In summary, using PLGA nanoparticles loaded with the VCAM-1 inhibitor succinobucol and the chemotherapeutic doxorubicin provides a promising drug nano-delivery strategy combining anti-primary tumor therapy and anti-lung metastasis therapy for metastatic malignant tumors. Here, VCAM1 is linked to neoplasm.